South Korea · Delayed Price · Currency is KRW HansBiomed Statistics
Total Valuation
HansBiomed has a market cap or net worth of KRW 353.90 billion. The enterprise value is 386.28 billion.
| Market Cap | 353.90B |
| Enterprise Value | 386.28B |
Important Dates
The next estimated earnings date is Friday, December 19, 2025.
| Earnings Date | Dec 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HansBiomed has 12.99 million shares outstanding. The number of shares has increased by 2.92% in one year.
| Current Share Class | 12.99M |
| Shares Outstanding | 12.99M |
| Shares Change (YoY) | +2.92% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.99% |
| Owned by Institutions (%) | 0.67% |
| Float | 7.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.14 |
| PB Ratio | 5.69 |
| P/TBV Ratio | 5.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 226.03, with an EV/FCF ratio of -105.32.
| EV / Earnings | -38.75 |
| EV / Sales | 4.51 |
| EV / EBITDA | 226.03 |
| EV / EBIT | n/a |
| EV / FCF | -105.32 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.05 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | 8.12 |
| Debt / FCF | -11.66 |
| Interest Coverage | -0.00 |
Financial Efficiency
Return on equity (ROE) is -15.31% and return on invested capital (ROIC) is -0.00%.
| Return on Equity (ROE) | -15.31% |
| Return on Assets (ROA) | -0.00% |
| Return on Invested Capital (ROIC) | -0.00% |
| Return on Capital Employed (ROCE) | -0.00% |
| Revenue Per Employee | 308.94M |
| Profits Per Employee | -35.98M |
| Employee Count | 277 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, HansBiomed has paid 1.92 billion in taxes.
| Income Tax | 1.92B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +241.48% in the last 52 weeks. The beta is 1.56, so HansBiomed's price volatility has been higher than the market average.
| Beta (5Y) | 1.56 |
| 52-Week Price Change | +241.48% |
| 50-Day Moving Average | 15,937.00 |
| 200-Day Moving Average | 10,094.05 |
| Relative Strength Index (RSI) | 59.12 |
| Average Volume (20 Days) | 1,166,811 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HansBiomed had revenue of KRW 85.58 billion and -9.97 billion in losses. Loss per share was -768.17.
| Revenue | 85.58B |
| Gross Profit | 53.59B |
| Operating Income | -314,530 |
| Pretax Income | -8.52B |
| Net Income | -9.97B |
| EBITDA | 5.26B |
| EBIT | -314,530 |
| Loss Per Share | -768.17 |
Balance Sheet
The company has 10.21 billion in cash and 42.76 billion in debt, giving a net cash position of -32.54 billion or -2,505.69 per share.
| Cash & Cash Equivalents | 10.21B |
| Total Debt | 42.76B |
| Net Cash | -32.54B |
| Net Cash Per Share | -2,505.69 |
| Equity (Book Value) | 62.23B |
| Book Value Per Share | 4,803.56 |
| Working Capital | 2.69B |
Cash Flow
In the last 12 months, operating cash flow was -1.64 billion and capital expenditures -2.03 billion, giving a free cash flow of -3.67 billion.
| Operating Cash Flow | -1.64B |
| Capital Expenditures | -2.03B |
| Free Cash Flow | -3.67B |
| FCF Per Share | -282.42 |
Margins
Gross margin is 62.62%, with operating and profit margins of -0.00% and -11.65%.
| Gross Margin | 62.62% |
| Operating Margin | -0.00% |
| Pretax Margin | -9.95% |
| Profit Margin | -11.65% |
| EBITDA Margin | 6.15% |
| EBIT Margin | -0.00% |
| FCF Margin | n/a |
Dividends & Yields
HansBiomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.92% |
| Shareholder Yield | -2.92% |
| Earnings Yield | -2.82% |
| FCF Yield | -1.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HansBiomed has an Altman Z-Score of 1.49 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.49 |
| Piotroski F-Score | 3 |